Global Marketing Leader, 2xTED Speaker & Board Member | Helping Pharma, Biotechs, Medical Device companies, Diagnostic Labs & Hospitals build Quality Focused Patient Driven Supply Chains
It is encouraging to see how the big players of the #pharma industry, like Merck are all-in to foster promising #oncology breakthroughs. T-Cell engagers are molecules designed to bind both to target antigens in cancerous cells and to immune T Cells to "engage" them, recognize and attack the tumors. #healthcareinnovation #oncology #fightcancer #immunotherapy
Today, we announced the completion of our acquisition of Harpoon Therapeutics. This acquisition expands our diverse oncology pipeline with the addition of novel T cell engagers designed to harness the power of the body’s immune system being investigated to help certain patients suffering from cancer and other diseases. We are excited to advance this important area of research and welcome our colleagues from Harpoon to our company. Read our news here: msd.gl/3TbUpqX
